Forteo (teriparatide; Eli Lilly) Drug Overview 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Forteo" report has been added to ResearchAndMarkets.com's offering.

Forteo (teriparatide; Eli Lilly) is a recombinant N-terminal fragment (amino acids 1-34) of human parathyroid hormone (PTH). Endogenous PTH plays a central role in the regulation of calcium and phosphate metabolism in mammals and acts to regulate bone remodeling. PTH is a direct anabolic agent in bone tissue and acts to stimulate the formation of new bone by activating osteoblasts. The 34 N-terminal amino acids contained in Forteo are the biologically active region of PTH, and Forteo has the same biological functions. Forteo acts to increase skeletal mass and bone strength and is not detrimental to the skeleton, unlike a continuous excess of endogenous PTH.

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Forteo: Osteoporosis

List of Figures

Figure 1: Forteo for osteoporosis - SWOT analysis

Figure 2: Drug assessment summary of Forteo for osteoporosis

Figure 3: Drug assessment summary of Forteo for osteoporosis

List of Tables

Table 1: Forteo drug profile

Table 2: Forteo pivotal trial data in osteoporosis

Table 3: Forteo late-phase trial data in osteoporosis

For more information about this report visit https://www.researchandmarkets.com/research/jtrckc/forteo?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs